Renal denervation to improve heart failure
Recruiting
- Conditions
- Systolic heart failure
- Registration Number
- NL-OMON25325
- Lead Sponsor
- Erasmus Medical CenterRotterdam, the Netherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1. Age ¡Ý18 and ¡Ü75 years;
2. Systolic ejection fraction (established on echo) <35%;
Exclusion Criteria
1. Pregnancy;
2. Renal artery abnormalities;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary efficacy endpoint<br>Change in iodine 123 meta-iodobenzylguanidine (123I-mIBG) heart to mediastinum ratio at 6 months.<br><br /><br /><br>Primary safety endpoint<br /><br>The occurrence of a combined endpoint of cardiovascular death, rehospitalization for heart failure, and acute kidney injury at 6 months.
- Secondary Outcome Measures
Name Time Method